Chairman of the Board: Ahmed HammamEditor-in-Chief: Ayman Badra
Why a Long-Term Mega Deal for Tarik Skubal Isn't as Risky as It Seems
Articles · 00:57:58 - Tuesday, November 17, 2026
Articles

Why a Long-Term Mega Deal for Tarik Skubal Isn't as Risky as It Seems

As the top prize of the upcoming free-agent class, two-time Cy Young winner Tarik Skubal is projected to command an 8- to 10-year contract exceeding $400 million. While many view such a commitment as a massive risk, a closer look at his track record, workload, injury history, and the aging patterns of elite pitchers suggests the deal could actually be a bargain.

Dominant Track Record and Manageable Workload

Since returning from surgery in 2023, Skubal has been arguably the best pitcher in baseball. Over his age-26 to age-29 seasons he made 103 starts, posting a 50-20 record with a 2.47 ERA (169 ERA+), 0.92 WHIP, and 757 strikeouts in 626⅓ innings while walking just 109 batters (1.6 per nine). His postseason resume is equally impressive: eight starts, 2.13 ERA, 0.79 WHIP, 70 strikeouts against nine unintentional walks in 50⅔ innings. Importantly, his career regular-season workload sits at only 925⅓ innings — well below the 1,000-inning threshold even when playoff innings are added. For comparison, Justin Verlander had thrown 1,553⅔ innings by the same age.

Age and Injury History in Context

Skubal turns 30 next season and has undergone Tommy John surgery in college, flexor tendon surgery in 2022, and an arthroscopic procedure in 2026. However, modern pitchers routinely return from such procedures to perform at a high level. Skubal missed only about six weeks after his latest surgery, then made 19 starts with a 2.73 ERA and 141 strikeouts in 115⅓ innings. The notion that his injury history makes a long-term deal perilous overlooks how common arm surgeries have become and how effectively pitchers recover.

Elite Pitchers Age Gracefully

Recent history shows that top-tier starters often remain productive well into their mid-30s. Verlander won Cy Young awards at 36 and 39; Max Scherzer was still elite at 37; Chris Sale captured a Cy Young at 35 and excelled at 37; Zack Wheeler posted 6.1 WAR at 36 after thoracic outlet surgery; Jacob deGrom recorded a 2.97 ERA in 30 starts at 37; Sonny Gray went 18-5 with a 2.72 ERA at 36; and Zack Greinke remained effective at 38. An eight-year deal for Skubal would cover his age-30 through age-37 seasons — a window where many aces have thrived.

Recent Mega-Deals for Pitchers Have Mostly Paid Off

A review of the largest pitcher contracts in the past decade reveals few true busts. Gerrit Cole (9 years, $324M) has delivered a Cy Young, multiple top-four finishes, and 22.4 WAR despite a Tommy John absence. Max Scherzer (7 years, $191.4M) produced 41.8 WAR, two Cy Youngs, and a World Series title. CC Sabathia (9 years, $202M) accumulated 27.1 WAR and five 200-inning seasons. Even deals like David Price's (7 years, $217M) yielded a World Series win and a 118 ERA+. The only clear disappointment was Stephen Strasburg, yet his 2019 World Series heroics justified the investment for Washington.

Value Measured in Wins Above Replacement

Using a conservative $8 million per WAR valuation, Skubal's performance has been worth approximately $48.4 million in 2024, $53.7 million in 2025, and $41.7 million last season — far exceeding his actual earnings. Over a 10-year, $400 million contract, he would need to average just 5 WAR per year to break even, a threshold his recent output suggests he can comfortably surpass.

Given his combination of elite performance, low career innings, proven durability after surgery, and the precedent of aces aging well, a long-term commitment to Tarik Skubal looks less like a gamble and more like a sound investment for a franchise seeking a cornerstone ace.

Share this article: